Men in prostate cancer prevention trial more likely to undergo biopsy
the ONA take:
According to new study published in the journal Cancer Epidemiology, Biomarkers and Prevention, men without prostate cancer taking part in the Prostate Cancer Prevention Trial who participate in other aspects of the trial are most likely to undergo a challenging biopsy.
The randomized, double-blind Prostate Cancer Prevention Trial studied the efficacy of finasteride, a 5-alpha reductase inhibitor, for the prevention of prostate cancer.
Researchers analyzed 13,000 healthy men over a 7-year period to identify which factors were linked with an increased willingness to undergo a biopsy. Researchers identified adherence to finasteride, keeping appointments, undergoing required tests, and good health as factors that increased willingness to undergo the procedure.
Among those who underwent a biopsy, 84% were adherent to finasteride and 98% had the required tests (PSA and digital rectal exam) versus 47% and 75%, respectively, of those who did not undergo a biopsy. They also observed an increased willingness to undergo a biopsy if the study site recruited greater than 200 participants and/or had resources that encouraged continued participation throughout the long-term trial.
Monitoring adherence behaviors can allow researchers to identify those may be less willing to comply with study requirements and create strategies to improve adherence for future studies.
Those who participate in other aspects are most likely to undergo a challenging biopsy.
The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for prostate cancer prevention.
This study was conducted by SWOG – a cancer research cooperative group that designs and conducts multidisciplinary clinical trials.
Researchers at The University of Texas MD Anderson Cancer Center and the Fred Hutchinson Cancer Research Center used a systematic model to identify factors associated with men adhering to the end-of-study (EOS) biopsy requirement of the trial.
The EOS biopsy, an invasive procedure that examines the cells or tissues of the prostate gland to determine if cancer is evident, is an important part of the study.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|